TICKERNERD
Menu
RNAZRNAZHealthcare · Biotechnology

RNAZ Stock Forecast: TransCode Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$1.74
+4.19% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 28 Oct 2026 — in the weakest quartile.

Market cap
$29.5M
Ticker Nerd rank
22/ 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$6.2M
Net income−$6.8M
Free cash flow−$5.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.8%
1M
+1.8%
YTD
−74.5%
1Y
−86.3%
From 52W high
−86.3%
From 52W low
+12.6%
$2
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RNAZ stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores TransCode Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
22/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
85
Quality
75
Value
53
Accruals
41
Growth
27
Revisions
25
Volatility
20
Issuance
18
Momentum
4

Size (85): Smaller than most of the companies we track.

Momentum (4): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RNAZ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RNAZ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$2$4$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26RNAZ

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 Apr 2025HC Wainwright & Co.MaintainsBuy$20 → $10
13 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Feb 2025HC Wainwright & Co.ReiteratesBuy—
6 Feb 2025HC Wainwright & Co.ReiteratesBuy—
18 Dec 2024HC Wainwright & Co.MaintainsBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2024HC Wainwright & Co.ReiteratesBuy—
6 Sept 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
29 May 2024HC Wainwright & Co.ReiteratesBuy—
16 May 2024HC Wainwright & Co.ReiteratesBuy—
16 Apr 2024HC Wainwright & Co.ReiteratesBuy—
3 Apr 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2023HC Wainwright & Co.ReiteratesBuy$3.00
15 Aug 2023HC Wainwright & Co.ReiteratesBuy$12
15 Nov 2022HC Wainwright & Co.MaintainsBuy$10 → $6.00
7 June 2022HC Wainwright & Co.InitiatesBuy$10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

RNAZ appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RNAZ vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, TransCode Therapeutics, Inc. returned −86.3% against +13.6% for the S&P 500, dividends included.

RNAZ vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26RNAZS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RNAZ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

TransCode Therapeutics, Inc. (RNAZ) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 76% of US stocks

Price / sales
—
Price / book
0.0×

Cheaper than 92% of US stocks

EV / EBITDA
−7.4×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−59.3%

Higher than 19% of US stocks

Return on assets
−19.9%

Higher than 19% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

TransCode Therapeutics, Inc. (RNAZ) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • TransCode Therapeutics, Inc. has a market value of $29.5M and an enterprise value of $187.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$42.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$22.6M.

  • Shares outstanding: 950,302.

  • Trailing P/E: 0.0×; forward P/E: −2.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • TransCode Therapeutics, Inc. employs 12 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

RNAZ vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RNAZTransCode Therapeutics, Inc.$29.5M22
ABVCABVC BioPharma, Inc.$29.1M13
NXTCNextCure, Inc.$29.0M70
CELUCelularity, Inc.$30.5M32
MGXMetagenomi Therapeutics, Inc.$30.9M31
CVMCEL-SCI Corp.$28.0M40
EYPTEyePoint, Inc.$31.2M12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own TransCode Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RNAZ news & analysis

TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio

PRNewsWire · 28 Oct 2026neutral

TransCode Therapeutics announced that its Board has begun a formal strategic process, with Tungsten Advisors retained to lead it. The process will consider potential transactions involving TTX-MC138 and the company’s other oncology programs, including licensing and development partnerships.

Why it matters — RNAZ watchers may follow the process for its potential implications for TTX-MC138, which is in Phase 2a development for ctDNA-positive colorectal cancer after curative-intent treatment.

TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026

PRNewsWire · 26 Oct 2026positive

TransCode Therapeutics presented poster 1025P at the 2026 ESMO Congress, reporting Phase 1a clinical data for TTX-MC138 in patients with advanced solid tumors. The poster highlighted durable disease control, acceptable tolerability, and exploratory evidence of treatment-associated antitumor immune activity.

Why it matters — The presentation offers RNAZ watchers an update on early clinical findings for its TTX-MC138 program.

TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026

PRNewsWire · 19 Oct 2026positive

TransCode Therapeutics announced that a poster on its lead candidate TTX-MC138 has been accepted for presentation at the ESMO Congress 2026 in Madrid on October 23. The poster will highlight the latest clinical update from the Phase 1a evaluation in patients with advanced solid tumors.

Why it matters — RNAZ watchers can follow the planned presentation for an update on the early-stage clinical evaluation of TTX-MC138.

TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up

PRNewsWire · 28 Sept 2026positive

TransCode Therapeutics reported updated follow-up data from its ongoing Phase 1a clinical trial of TTX-MC138 in heavily pretreated patients with advanced solid tumors. In the 14 efficacy-evaluable patients, 71.4% achieved stable disease, 57.1% had disease control through three months, 36.7% through six months, and three patients remained progression-free at one year, with the primary endpoint met and no dose-limiting toxicities reported. Exploratory blood RNA-sequencing indicated treatment-associated antitumor immune activation and biological features linked to stable disease.

Why it matters — This update strengthens evidence of TTX-MC138's antitumor activity and extended disease stabilization in a difficult-to-treat patient population, which is relevant to RNAZ watchers assessing the drug's clinical progress.

FAQ

Frequently asked questions about RNAZ stock

Is RNAZ stock a buy right now?

Of the 1 analysts covering TransCode Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TransCode Therapeutics, Inc. 22 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RNAZ?

As at 28 Oct 2026, TransCode Therapeutics, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (85 of 100).

What is the RNAZ stock forecast for 2030?

No analyst covering TransCode Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNAZ are extrapolating price history, which says nothing about the business.

How has RNAZ stock performed over the past year?

TransCode Therapeutics, Inc. returned -86.3% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TransCode Therapeutics, Inc. do?

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies and immuno-oncology programs for high-risk and advanced cancers.

What is the latest news on RNAZ?

The most recent item we track (PRNewsWire, 28 Oct 2026): "TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio". TransCode Therapeutics announced that its Board has begun a formal strategic process, with Tungsten Advisors retained to lead it. The process will consider potential transactions involving TTX-MC138 and the company’s other oncology programs, including licensing and development partnerships.

Company

About TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies and immuno-oncology programs for high-risk and advanced cancers. The company’s current work centers on targeted cancer therapeutics designed to address metastatic disease, including candidates that modulate microRNA pathways and other genetic mechanisms linked to tumor growth and spread. Its pipeline also includes programs exploring RNA delivery platforms and combination approaches aimed at improving how nucleic-acid medicines reach cancer cells. TransCode Therapeutics operates within the oncology and RNA therapeutics segments of the life sciences market, where it contributes to the development of precision treatments for difficult-to-treat malignancies. Headquartered in Boston, Massachusetts, the company concentrates on advancing experimental cancer therapies through clinical and preclinical development.

CEO Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. · 12 employees · United States · https://www.transcodetherapeutics.com